EXAI vs. RLAY, ABCL, SDGR, ADMA, CGON, RXRX, NVAX, KYMR, BEAM, and FUSN
Should you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), Schrödinger (SDGR), ADMA Biologics (ADMA), CG Oncology (CGON), Recursion Pharmaceuticals (RXRX), Novavax (NVAX), Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "medical" sector.
Relay Therapeutics (NASDAQ:RLAY) and Exscientia (NASDAQ:EXAI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
Relay Therapeutics has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, Exscientia has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Exscientia has higher revenue and earnings than Relay Therapeutics. Exscientia is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Exscientia has a net margin of -666.80% compared to Exscientia's net margin of -1,263.49%. Relay Therapeutics' return on equity of -34.59% beat Exscientia's return on equity.
Relay Therapeutics received 30 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 60.94% of users gave Relay Therapeutics an outperform vote while only 36.00% of users gave Exscientia an outperform vote.
In the previous week, Exscientia had 14 more articles in the media than Relay Therapeutics. MarketBeat recorded 16 mentions for Exscientia and 2 mentions for Relay Therapeutics. Exscientia's average media sentiment score of 0.94 beat Relay Therapeutics' score of 0.42 indicating that Relay Therapeutics is being referred to more favorably in the media.
97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 41.6% of Exscientia shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Relay Therapeutics currently has a consensus price target of $22.20, indicating a potential upside of 227.92%. Exscientia has a consensus price target of $9.75, indicating a potential upside of 104.83%. Given Exscientia's stronger consensus rating and higher probable upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Exscientia.
Summary
Relay Therapeutics beats Exscientia on 11 of the 18 factors compared between the two stocks.
Get Exscientia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exscientia Competitors List
Related Companies and Tools
